viewe-Therapeutics PLC

e-Therapeutics granted US patent for key process


Drug discovery and development specialist e-Therapeutics (LON:ETX) announced today it had been granted a US patent for a further key process in its drug discovery platform.

The patent, dubbed ‘Power behind the Throne’, is the third platform patent granted to e-Therapeutics in the US and it represents what the firm said is an “important addition” to the intellectual property estate covering its network pharmacology technology.

e-Therapeutics applies the science of complex systems to discover new drugs. The company characterises the network of proteins important in a particular disease, then proceeds to identify optimal means of disrupting that network.

This involves understanding the role of each protein in network terms, as a node linked to other network components. The new patent covers a process used to identify nodes that are essential to the integrity of a network but which exert their influence indirectly. This feature of indirect influence is the reason for the patent’s ‘Power behind the Throne’ title.

“This patent reflects the innovations we are making as we continue to develop our platform technology,” said professor Malcolm Young, e-Therapeutics’ chief executive officer. “Its grant coincides with the start of a major new wave of discovery activity employing our network pharmacology approach.”

e-Therapeutics restarted its discovery effort in July, with new work focused on cancer and degenerative diseases of the nervous system. At the time, the firm also outlined plans for clinical development of four candidates resulting from earlier discovery projects.

“We expect significant developments in the near future in two areas of our business,” added Young. “One is discovery, where we expect to generate new product candidates in areas of great unmet medical need. The other is development, where we look forward to the start of a cascade of clinical data from our four leading candidates.”

Quick facts: e-Therapeutics PLC

Price: 14.3 GBX

Market: AIM
Market Cap: £59.93 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics PLC named herein, including the promotion by the Company of e-Therapeutics PLC in any Content on the Site, the Company receives...


2 min read